JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, published by SPRINGER, is a leading peer-reviewed journal dedicated to advancing the field of endocrinology. With a remarkable history dating back to 1978 and a convergence set until 2024, this journal serves as a vital source for researchers, clinicians, and students focusing on the intricate interplay of hormonal regulation and its implications for health and disease. The journal is recognized in the Q2 category for both Endocrinology and Endocrinology, Diabetes and Metabolism, highlighting its relevance and impact within the scientific community, exemplified by its strong Scopus rankings. While it does not offer open access, it ensures that high-quality research, reviews, and significant clinical findings are accessible to its readership. With a commitment to improving patient outcomes and elucidating complex biological mechanisms, the JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION remains a cornerstone publication for anyone involved in the study or practice of endocrinology.

Journal fur Hypertonie is a leading academic journal published by KRAUSE & PACHERNEGG GMBH, dedicated to the critical field of hypertension research. Since its inception in 1998, the journal has served as a vital platform for disseminating pioneering studies and advancements in the diagnosis, treatment, and management of hypertension. Although its Scopus coverage was discontinued in 2016, the journal continues to hold significance within the academic community, evidenced by its ranking of #98 out of 124 in Internal Medicine, placing it in the 21st percentile. This reflects its targeted impact and relevance in the evolving landscape of cardiovascular research. With no Open Access options, the journal remains a specialized resource indispensable for researchers, healthcare professionals, and students focused on enhancing their understanding and clinical practices related to hypertension. The journal's address is MOZARTGASSE 10, GABLITZ 3003, AUSTRIA.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

Diabetes Metabolic Syndrome and Obesity is a leading open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing research in the fields of diabetes, metabolic syndrome, and obesity. Since its inception in 2008, the journal has aimed to disseminate high-quality, peer-reviewed articles that contribute to our understanding of these prevalent health issues, with a special focus on clinical practices, therapeutic advancements, and epidemiological studies. Boasting a commendable Q2 ranking in both Internal Medicine and Pharmacology for 2023, the journal is placed among the top tier of its category, with a Scopus ranking of #44 out of 167 in Internal Medicine and #124 out of 313 in Pharmacology. This positions the journal in the 73rd and 60th percentiles, respectively, highlighting its significance in the academic community. Researchers and professionals are encouraged to utilize this journal as a valuable resource for access to groundbreaking studies and developments in the treatment and management of diabetes and related metabolic disorders, contributing to global health improvements.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

HYPERTENSION, published by Lippincott Williams & Wilkins, is a preeminent journal in the field of cardiovascular medicine, focusing on the latest research, therapies, and clinical practices related to hypertension and its associated disorders. With a distinguished Q1 ranking in Internal Medicine and a commendable Scopus rank of #12 out of 167 in its category, it occupies a vital position within the academic community, appealing to researchers, clinicians, and educators alike. The journal has been disseminating impactful findings since 1979 and continues to influence the discourse on hypertension through rigorous peer-reviewed articles, reviews, and studies designed to elevate understanding and treatment of this prevalent condition. HYPERTENSION remains an essential resource for professionals keen on advancing their knowledge in this critical area of medicine, fostering innovations that ultimately improve patient care.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, published by SAGE PUBLICATIONS INC, stands as a vital resource in the fields of Endocrinology and Internal Medicine. With an impressive open access model established in 2014, this journal facilitates broad dissemination of high-quality research that explores the complex mechanisms and clinical implications of the renin-angiotensin-aldosterone system (RAAS). Currently, it is recognized within the 2023 Category Quartiles as Q3 in Endocrinology and Q2 in Internal Medicine, reflecting its significant impact on the scientific community. The journal ranks in the 75th percentile for Internal Medicine and the 57th percentile in Endocrinology according to Scopus, indicating its strong contributions to these disciplines. Covering a rich history from its inception in 2000 to the present, the journal aims to bridge the gap between basic research and clinical practice, thereby enhancing the understanding and treatment of conditions influenced by RAAS. The continuous publication of innovative research makes it an essential reference for researchers, healthcare professionals, and students engaged in these dynamic fields.

Clinical Medicine Insights-Cardiology is a prestigious open-access journal published by SAGE Publications Ltd, focusing on cutting-edge research in the field of cardiology and cardiovascular medicine. With the ever-evolving landscape of cardiovascular health, this journal serves as a vital platform for disseminating significant findings, clinical practices, and innovative therapies. Established in 2007, it has rapidly gained recognition, currently ranked in the Q2 category for cardiology, positioned at #112 out of 387 in Scopus Rankings, and boasting a commendable 71st percentile. The journal not only emphasizes the integration of recent advancements in clinical and laboratory studies but also aims to bridge the gap between research and practice, making it an essential resource for researchers, healthcare professionals, and students alike. Situated in New Zealand and operating with an open-access model, Clinical Medicine Insights-Cardiology promotes the unrestricted dissemination of knowledge, ensuring that critical insights into cardiovascular medicine are accessible globally.